We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Dermacyd Femina Pocket BR (Lactic Acid)- Acceptability.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00794612
Recruitment Status : Completed
First Posted : November 20, 2008
Last Update Posted : December 19, 2008
Information provided by:

Study Description
Brief Summary:
The purpose of this study is to prove the safety of the gynaecological formulation in normal conditions of use.

Condition or disease Intervention/treatment Phase
Hygiene Drug: Dermacyd Femina Pocket BR (Lactic Acid) Phase 3

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Safety Dermatological Evaluation: Genital Mucous Irritation - Test in Use - Dermacyd Femina Pocket BR (Lactic Acid).
Study Start Date : November 2008
Primary Completion Date : November 2008

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: 1
Dermacyd Femina Pocket BR (Lactic Acid)
Drug: Dermacyd Femina Pocket BR (Lactic Acid)
Dermacyd Femina Pocket BR (Lactic Acid) during 21 consecutive days

Outcome Measures

Primary Outcome Measures :
  1. Absence of irritation [ Time Frame: From the start to the end of the study ]
  2. Good acceptability [ Time Frame: From the start to the end of the study ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion criteria:

  • Integral skin test in the region;
  • To use products of the same category;

Exclusion criteria:

  • Lactation or gestation;
  • Use of anti-inflammatory, anti-histaminic or immunosuppressant drugs;
  • Cutaneous disease (local or spread) in the evaluation area;
  • Pathology which may cause immunity depression, such as HIV, diabetes;
  • Endocrine pathology
  • Solar exposure 15 days before evaluation;
  • Treatment until four months before the selection.
  • Allergic or atopic history to cosmetics products

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00794612

Sanofi-Aventis Administrative Office
Sao Paulo, Brazil
Sponsors and Collaborators
Study Director: Jaderson Lima Sanofi
More Information

Additional Information:
Responsible Party: Medical Affairs Study Director, sanofi-aventis
ClinicalTrials.gov Identifier: NCT00794612     History of Changes
Other Study ID Numbers: LACAC_L_04369
First Posted: November 20, 2008    Key Record Dates
Last Update Posted: December 19, 2008
Last Verified: December 2008